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Analysis of the Tumor Vasculature and 
Metastatic Behavior of Xenografts of Human 
Melanoma Cell Lines Transfected with Vascular 
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Vascular permeability f a c to r  (VPF) is an im por­
tant mediator o f  vascu lar development in tu­
mors, Some human melanoma cell lines have a  
low VPF expression level in culture, hut this level 
is up regulated when grow ing as a tum or in nude  
mice. Other melanoma lines have a cons tit it lively 
high VPF expression. To com pare the biological 
behavior o f  tumors with  these two expression  
patterns , a human melanoma cell line with an 
inducible VPF expression  tvas transfected with  
VPF expression constructs. In this  aw y, several  
lines were obtained that constitutively p ro d u ce  
either the soluble VPFltlt o r  the m atrix-associ­
ated VPF tm variant at levels o f  4 to JO times the 
VF F level in mature tum ors derived  fro m  the p a ­
rental line. The recombinant VPF IWA, which  
lacks most o f  t he 5' noncoding sequences present 
in the endogenous VPF mPNA, tvas much more  
efficiently translated than the endogenous m es­
senger. Upon injection In nude mice* all VPF- 
transfected lines developed tumors with aberra ­
tions in vascularization and in distribution o f  
matrix components. In these tumors the blood  
vessels were h yp e tp erm ea b le fo r  an l.v. injected  
protein tracer; Transfection d id  not influence the 
in vitro grow th  rate o f  the ceil lines , but the 
tumors front the VPFdransfected lines had  
higher growth rates  in v iv o  than tum ors f r o m  the 
parental line o r  the vector-transfected line. Al­
though the incidence o f  lung met erst as is tvas s im ­
ilar in all lines, the number o f  m étastasés p e r
affected lung was significantly increased in mice 
carrying VPF-transfectant tun tor s. We conclude 
that the p a t  tern and the level o f  VPF expression  
in a tum or are  important determinants o f  the 
architecture and functionality o f  the vascular  
bed , but that overexpression  o f  VPF does not 
necessarily lead to an increase o f  microvascular  
density or metastatic spread. The role o f  VPF in 
melanoma progression  is obviously complex and  
may be difficult to derive in its generality fro m  a 
single experim ental model. (Am f  Pathol 1996 
148:1203-1217)
Angiogenesis, the formation of now blood vessels 
from existing vessels, is a process essential for tu­
mor growth. Tumors without a vascular bed do not 
grow beyond a diameter oi 1 to 2 mm3.1 In addition, 
tumor metastasis is dependent on angiogenesis, as 
blood vessels provide the most important escape 
route for disseminating tumor cells.1 3 In recent stud- 
ies a correlation between tumor vascularization and 
metastatic risk has indeed been demonstrated/1 M 
Qutgrowlh and malignant behavior of a lurnor there 
fore is accompanied by rapid development of the 
tumor vasculature, and, perhaps because of this, 
tumor blood vessels often have a chaotic architec­
ture besides other characteristics that are distinct 
from normal blood vessels (reviewed In refs, 9 and 
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macromolecules is often higher than in normal blood 
vessels,9,10 although this permeability differs signif­
icantly between various tumor types.11 Vascular per­
meability has also been shown to be lower in tumor- 
penetrating vessels than in a vascular plexus at the 
tumor-host interface.12,13 Tumor blood vessels are 
often prone to intravascular coagulation, leading to 
deposition of fibrin and the occurrence of intravas­
cular thrombi. ’M
The development of the tumor vascular bed is 
thought to be mediated by a number of tumor-de­
rived angiogenic growth factors and cytokines (re­
viewed in refs. 2 and 15; see also refs. 16 and 17). 
Among these factors, vascular permeability factor/ 
vascular endothelial growth factor (VPF/VEGF) is 
gaining attention, as it has become clear that it is an 
essential factor in tumor angiogenesis and tumor 
growth.18"20 The main targets of VPF are endothelial 
cells, which are almost the only cells expressing VPF 
receptors.21“25 The capacity of VPF to induce angio­
genesis is probably due to the induction of a variety 
of functions in the endothelial cell, including proteo­
lytic activity, chemotaxls, and proliferation.21,26'"2tt 
VPF may also be responsible for other characteris­
tics of the tumor vasculature, such as vascular hy­
perpermeability29,30 and intravascular coagulation 
(via the induction of tissue factor expression on en­
dothelial cells31). By enhancing tumor vessel perme­
ability, VPF may contribute indirectly to angiogene­
sis, as fibrinogen leaking from the vessels can form 
an extravascular fibrin matrix serving as a substrate 
for endothelial outgrowth 3y
In a previous report we described that a human 
melanoma cell line, Me!57, expressed low VPF mes­
senger and protein levels in culture, but contained 
elevated levels of VPF mRNA after injection into nude 
mice and the formation of a tumor,33 Hypoxia was 
shown to be a likely mediator of this VPF upregula- 
tion. The tumors from this melanoma line had a char­
acteristic vascular pattern, with blood vessels pene­
trating the tumor parenchyma in an apparently 
random fashion, This melanoma line was engineered 
into a line constitutively expressing VPF by transfec­
tion, Xenografted to nude mice, this line developed 
into tumors with a vascular pattern distinct from pa­
rental line tumors; these tumors consisted of several 
tumor cell nodules devoid of blood vessels and sep­
arated by robust stromal septa very rich in blood 
vessels.33
In the present study we have extended these find­
ings by generating a panel of VPF-transfected mel­
anoma lines expressing different molecular variants 
of VPF at different levels, The recombinant VPF RNA, 
lacking most of the 5' noncoding sequences of the
VPF gene, was translated into protein much more 
efficiently than the endogenous VPF messenger. We 
show that the altered VPF expression pattern in­
creased the permeability of the tumor blood vessels 
for macromolecules, the growth rate of the tumors in 
vivo , and the metastatic burden in the lungs.
Materials and Methods
Cell Culture
The human melanoma cell line Mel57 was cultured 
as previously described.3"1 Transfected Mel57 
cells were cultured in the same medium supple­
mented with 200 (JLQ/m\ hygromycin B (Boehringer 
Mannheim, Mannheim, Germany).
In Vitro Growth Assay
The growth of the Mel57 melanoma line and the 
transfectant lines was monitored using a non-radio­
active colorimetric assay based on a tétrazolium salt 
reaction as described originally by Mosman.3fl On 
day 0, parental and transfected melanoma cells 
were seeded in 96-well tissue culture plates at a 
concentration of 500 cells/well in 100 jxI culture me­
dium and allowed to adhere overnight. On day 1, the 
colorimetric signal was determined in an enzyme- 
linked immunosorbent assay (ELISA) reader to com­
pare the activity of the different cell types. In a num­
ber of wells, different amounts of recombinant 
human VPF/VEGF (Peprotech/Sanvertech, Breda, 
The Netherlands) were added on day 3. Medium was 
exchanged for fresh medium without additional VPF 
on days 5 and 8. Colorimetric activity was followed 
until day 11. In the experiments in which VPF was 
added, the results are expressed as the mean value 
SD of four different readings, For the determination 
of the in vitro growth curves, the mean value 1 SD of 
24 different measurements was calculated. For sta­
tistical analysis a Student’s Mest for unpaired values 
was used.
mi«
Production o f Stable Transfectants
The protein coding regions o( VPF,,,, and VPF 
were obtained by reverse transcription polymerase 
chain reaction on RNA from cell line U937 and were 
subsequently cloned into vector pUC19. as do- 
scribed elsewhere.'''’1 After sequence analysis, the 
inserts were recloned between the Xba\ and Kpn\ 
sites of the plasmid EBOpLPP. " -' Plasmids with 
VPF,.,, and VPFW) inserts, as well as the empty 
vector, were linearized with Apa\, and the 7 to 8 kb
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fragments were isolated from low melting point aga­
rose gel slices and were transfected into Mel57 cells 
by calcium phosphate precipitation.37 Transfected 
clones were selected in medium with 200 ju,g/ml 
hygromycin B, removed by scraping, and expanded 
until analysis of the clones and storage of stocks in 
liquid nitrogen was possible (see also ref. 33).
Analysis of VPF Expression on the RNA and 
Protein Level
RNA from cell lines was isolated using guanidinium 
chloride according to Peek et al,37 and RNA from 
tumor xenografts was isolated by disruption in 
guanidinium isothiocyanate and CsCI centrifuga­
tion, as described in Sambrook et a\.3H Northern 
analysis and hybridizations with VPF and ubiquitin 
probes were performed as described earlier.33 To 
monitor VPF protein secretion, cells were cultured 
for 24 hours in serum-free medium lacking hygro­
mycin, containing 100 /xg/ml heparin. Conditioned 
media were cleared by centrifugation and used for 
VPF protein analysis. To correct for differences in 
cellular density, cells were scraped and lysed, and 
the cellular protein content was determined with a 
standard protein assay (Biorad, Veenendaal, The 
Netherlands). Based on this protein determination* 
samples of conditioned media derived from equal 
amounts of cell material were taken and tested in a 
procoagulant a s s a y . S i m i l a r l y ,  samples were 
concentrated fivefold, run on sodium dodecyl sul­
fate polyacrylamide gel electrophoresis (SDS- 
PAGE), and analyzed by Western blotting and 
staining with a polyclonal anliserum raised against 
Escherichia co//-produced VPF, as described else­
where. Staining was visualized by chernilumines- 
eonee on X-ray film and quantitated by densilom- 
Levels of human VPF protein in culture
supernatant were measured in an ELISA (R&D 
Systems, Inc., Minneapolis, MN), according to the 
manufacturer's specifications.
Xenografts from Line Mel5 7 and 
Transfectants in Nude Mice
About 2.5 x io r' cells were injected s.c. into 
BALB/c nu/nu mice as described in ref. 34. Every 
week tumor volumes were estimated. Tumors of 
between 300 and 1200 mm;l were harvested and 
cut into throe fragments. One part was formalin
were snap-frozen in liquid nitrogen; one was used 
for RNA isolations, the other to study the vascular 
patterns, the organization of extracellular matrix 
components, and the spatial distribution of VPF 
within the tumors (see below). To study vascular 
morphology in the early stages of tumor develop­
ment, for some lines also smaller tumors were 
taken (within 1 week after the occurrence of a 
palpable tumor), snap-frozen, and stained immu- 
nohistochemically. Acetone-fixed 4 jjuti cryosec- 
tions were stained with a rat monoclonal antibody 
(Ab), MEG 7.46, directed against mouse vascular 
endothelium (a gift from Dr. A. Vecchi, Milano, 
Italy41), a rabbit polyclonal Ab against mouse lami- 
nin (a gift from Dr. J. van den Born, Department of 
Nephrology, University Hospital Nijmegen), a goat 
polyclonal Ab against (human) heparan-sulfate 
proteoglycan (HSPG, a gift from Dr. L. van den 
Heuvel, Department of Pediatrics, University Hos­
pital Nijmegen), or with a rabbit polyclonal Ab 
against human VPF/VEGF (Santa Cruz Biotechnol­
ogy, Santa Cruz, CA; Sanvertech, Breda, The 
Netherlands). For visualization of the immune re­
actions, alkaline phosphatase-conjugated sec­
ondary Ab were used, except for the anti-HSPG 
reaction, which was visualized using a peroxidase- 
conjugated donkey anti-goat Ab. All sections were 
counterstained with hematoxylin.
For the analysis of tumor vessel permeability, mice 
bearing tumors with sizes between 100 and 700 rnm;i 
were i.v. injected with 0.1 ml of a 3% solution of 
fluorescein isothiocyanate-bovine serum albumin 
(FITC-BSA) (11 rnol FITC/mol BSA; Sigma, Brunsch- 
wig, Amsterdam, The Netherlands). Tumors were ex­
cised 2, 10, or 45 minutes after the injection of tracer, 
and snap-frozen In liquid nitrogen. Cryosections of 
these tumors, 4 /xrn thick, were immediately fixed in 
2% formaldehyde solution for 10 minutes. Tho distri­
bution of the tracer was shown by fluorescence mi­
croscopy. The deposition of extravasated fibrin was
in parallel acetone-fixed tumor sections 
with a goat polyclonal Ab against mouse fibrinogen/ 
fibrin (Nordic Immunological Laboratories, Tilburg,
ans
The Netherlands), using a peroxidase-conjugated 
donkey anti-goat secondary Ab. Other parallel sec­
tions of these tumors were stained for endothelium or 
HSPG (see above).
Metastasis of Transfectant Xenografts
To study the growth rate of transfected xenografts
"J  li* r
fixed, slained with hemaloxylin and eosin (H&E). and to estimate the frequency of metastasis and the 
and used to study overall tumor morphology and to number of metastases per mouse, two VPF-trans- 
assess the percentage of necrosis. The other parts fecled lines (I-3 and MI-8), and one vector-trans-
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Figure 1. Expression o f endogenous and ivannhinant 17V; RNA hy ¡nvhmoaut teff iraasflrurnts, A!artbvm blots conta in in# AVV.-t from celi ¡ines (A) 
or
wAW.
aso hand ofahonl U ) kb. Mel57: patvntal melanoma fine; l !J :  Unes tmnsfected trifb tvcforfW A only; ÍII-K Hue transfected with \VFìm c/h\A; 
/_.ƒ, i- y,* /-//.■ fines tra us fee ted tvfth W ,.., cfWA, Positions o f mofee (dar mass sia mff mis are indicated on both sides
l y u r ©  I .  f i x p r c \ s . S H ) f l  u j  v i i i i \ * # v n i * u >  a / K f  i v i i t m m N i i n i  r  / u v / i  r n  (t<*. w  m u m *  v * n  u u m m ,  s u m m u
•wentwajis hi nude iniceiB) were hybridized trifb a Yl}f'probe {upper portions» and  with ti ubit/nitin probe (lower portions), lindóle)tons T/V’ 
'A /l is t'isihh' as multiple hands around ,1 7kh it i tumor RNA tmfr, and recouibhtuttt lVV-'AVV.l is u/>]>arcnt in \ 'Pf'-transfected lines and tbeirtmuors
fected line (E2) were injected s.c. in 20 mice per 
group (4 x  10G cells/mouse). This regimen yielded a 
take rate of 100%. The tumor volume was monitored 
weekly and calculated as the product of three per­
pendicular measurements. Growth rates were plot­
ted as the mean of 20 measurements ± SD. Mice 
were sacrificed after 7 weeks, unless overt illness 
developed or the tumor grew excessively, in these 
cases (n — 11) mice were sacrificed at earlier time 
points. Mel57 tumor growth was determined by mea­
surements in a parallel group of 50 mice, where the 
mice were sacrificed at different time points after 
tumor take. In this group, tumor volume was deter­
mined at the time of tumor excision and expressed 
as the mean value of measurements in 4 to 10 mice. 
The transfectant tumors were excised, weighed, and 
divided in three parts for storage in liquid nitrogen 
and formalin (see above). Through the trachea, the 
lungs were filled with 1:4 diluted mounting solution, 
taken out, and divided In three parts. Two parts were 
formalin-fixed, and cross sections were H&E-stained 
and analyzed for tho occurrence of métastasés as
described in ref. 34. Scoring was performed by three 
independent observers. The number of métastasés 
found in two cross sections of both lungs was deter­
mined and the metastatic burden calculated as the 
mean number of métastasés per cross section. The 
metastatic frequency was defined as the number of 
mice having one or more lung métastasés divided by 
the number of mice in the group. For statistical anal­
ysis a Student's f-test for unpaired values was used.
Results
Selection of Melanoma Cell Transfectants
Mel57 is a melanoma line with a low level of VPF 
expression in culture, but an elevated level when 
growing as a tumor in nude mice. A transfectant of 
this line, producing VPFUM constitutively, had quite a 
different vascular pattern in mouse xenografts com­
pared with the parental line t u m o r s . T o  determine 
whether the level of recombinant VPF expression, or 
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the arrangement and the functionality of the tumor 
vasculature, we selected several other VPF.m - and 
VPF18Q-transfected melanoma lines.
The expression levels of the transfectants were 
determined by Northern blotting. In RNA from the 
VPF-transfected cell lines a band of approximately
1.0 kb was seen upon hybridization with a VPF 
probe, representing the recombinant VPF RNA 
(see Figure 1A). The highest levels of recombinant 
VPF RNA were produced by lines I-3 (expressing 
VPF ,P1, described before in ref. 33) and 111-8 (ex­
pressing VPFim)). Lines I-4,I-9, and 1-11 contained 
lower but still detectable levels of VPF1£M-encod- 
ing recombinant VPF RNA (see also Table 1), The 
major endogenous VPF transcript is 3.7 kb in 
length, but this was undetectable in RNA from cell 
line Mel57 or its derivatives. Southern blots of 
genomic DNA from transfected lines, digested 
with Hindi ill, showed multiple bands upon hybrid­
ization with a VPF probe, in addition to the bands 
deriving from the endogenous VPF gene (not 
shown), indicating that multiple copies of the 
transfected construct had been integrated.
To confirm that the recombinant VPF RNA levels 
found in the lines described above correlate with the 
amounts of active VPF protein secreted, conditioned 
serum-free media of these lines were harvested. The 
supernatants were Western blotted and stained with 
a polyclonal antiserum against VPF. In conditioned 
media of the parental line Mel57 and the vector- 
transfected lines E1 and E2, no VPF protein could be 
detected. Lines I-3 and I-4, expressing the RNA
E2 I-3 I-4 -8
encoding recombinant VPFt;M, secreted detectable 
amounts of 16 and 20 kd proteins (Figure 2), being 
the expected molecular masses of tho nonglycosy- 
ated and glycosylated forms of VPF,;,,/1"' Line 111-8,
expressing the RNA for recombinant VPF,M}„ se­
creted the expected VPF proteins of a molecular 
mass of 28 and 31 kd (Figure 2) but these proteins 
needed heparin to be released from extracellular
Figure 2. \ Vb'pntMn u\ptvssiuu hyAlvt*:? fnmsfcctitnls. I'mh'ltts uvtv 
atNccntrated fitvfhh! fnmt 10 ml tiiitjitofs <;f srrnm fnv auuiitimteil 
mvrtht of melanoma cell tntnsfcctauis, e/i'Ltn>plM nest'd wider nulm'iuM 
cwulUitnis, elceirohloltcd, and stained with a polychmai an/(scrum 
against banian VP!'. h'J: line timisfctiVif with nvtorDNA only; 1.1 I t :  
lines tnnisjh tcif with I VY''],., DNA, /// »S'; iinv tnnts/hkul with 
t'DNA. c.\nidt'iiont>tl media am taimui fOM ¡xiinit be/Htrin. i\* si thus of 
mokrular mass stautltmfs atv iutifcaied at the right.
matrix.^1'*13 The relative amounts of glycosylated and 
nonglycosylated protein were determined by densi­
tometry of the Western blots. The absolute levels of 
VPF protein were determined by ELISA (Table 2). 
VPF1i?1 appeared predominantly in the glycosylated 
form. A significant amount of VPF1B{) proved to be 
nonglycosylated (Figure 2), although the intensity of 
the VPF,HQ signal might have exceeded the maximal 
level. The ELISA analysis showed that the VPF-trans- 
fected lines I-3 and I-4 secreted 30 to 50 times more 
VPF than the nontransfected lines BLM and MV3. A 
trace of VPF was found in the Mel57 supernatant. 
Unfortunately, the ELISA appeared to be insensitive 
for VPF1tm; therefore, the VPF levels of line II1-8 could 
not bo measured. The reason for this insensitivity is 
unclear. Nonetheless, it could be derived from the 
densitometry results that line 111-8 produced VPF at a 
much higher level than 1-3 or 1-4, probably exceeding 
a final concentration of 1 /xg/rnl under the test con­
ditions, The biological activity of the recombinant 
VPF was tested in a procoaguiant assay, measuring 
the capacity to induce tissue factor expression on 
endothelial cells. No significant activity was present 
in the conditioned media of Mol57 and control trans-
Table 2. (¿naitlifiattitm  o f  177*' Pn>tein Lends in ( .hnd itioned  (,’nil are Medium
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fectants, but the fines that produced recombinant 
VPF were all positive in this assay (not shown). The 
highest tissue factor level was induced by condi­
tioned medium from line 1-3. Although no VPFie9 was 
detectable in the heparin-free conditioned medium 
of line ill-8 by Western blotting (not shown), sufficient 
VPF activity was present in this supernatant to cause 
a significant increase in the tissue factor level.
The Efficiency of Translation of Recombinant 
VPF RNA
The endogenous VPF mRNA has a 1 kb 5' noncod­
ing sequence in which a very GC-rich region and 
several alternative translational start sites are 
present."1" These features may inhibit the efficiency 
of translation of the VPF mRNA. The recombinant 
VPF RNA lacks these sequences; only a stretch of 21 
bases of the 5' noncoding sequence of the VPF gene 
is contained in the recombinant RNA* The efficiency 
of translation of the recombinant VPF RNA in Mel57 
transfectants was compared with that of the endog­
enous VPF messenger in melanoma line BLM, which 
has a constitutively high VPF expression.33
fn transfectant cell line I-9, no endogenous VPF 
mRNA was detectable; Its level of recombinant 
VPF1g1-encoding RNA (1 kb) was about the same (in 
a molar ratio) as the level of endogenous VPF mRNA 
in melanoma line BLM (3.7 kb, Figure 3A). The VPF 
mRNA in line BLM was previously shown to encode 
predominantly VPFlin along with some VPF1titi.33 
The VPF protein secreted by cell line BLM was barely 
detectable on Western blots (bands representing 
VPF121 and VPF1G{l can be seen between 16 and 24 
kd), whereas the VPF1S1 bands produced by line I-9 
are clearly visible (Figure 3B). Scanning of bands on 
autoradiographs from several Northern and Western 
blots revealed that VPF is 16- to 40-fold more effi­
ciently produced from recombinant VPF RNA in line 
i-9 than from the endogenous VPF messenger in line 
BLM. In estimating the expression levels of recom­
binant VPF protein in tumors, we have taken this 
higher efficiency of translation into account (see be­
low, and Table 1).
Expression of Recombinant VPF in 
Xenografts
Transfected melanoma lines positive for recombinant 
VPF expression, as well as the parental line Mel57 and 
vector-transfected lines E1 and E2, were injected into 
nude mice, and from the resulting tumors RNA was 
isolated. Northern blotting of these RNAs showed that 
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Figure 3. Analysis of the relative translation efficiency of recombinant 
VPF RNA. (A) Northern I)lot with RNA from melanoma cell line MM  
and from VPFu! -transfected cell line 1-9, hybridized with a VPF ¡m> be 
(upper panel) and a ubitfuitin pn>be (lower panel), length markers 
are indicated on the left. (B) Serum-free conditioned media contain- 
tug 100 fjL&ml heparin from melanoma cell line HIM and transfectant 
cell tine 1-9, were electropbo/vsed on SDS-PAG'Ii tinder reducing con­
ditions, electwbfotled, anti stained with polyclonal anti.senim against 
VTJ’X blocked before use with three rolumes o f heat-denaturedfetal calf 
svmm iFCS) to reduce nonspecific hackgmund). Loaded were 2»S'5 fit 
o f line Mhcondiihmed medium (as in Figure J) and ^00 fxl o f HIM- 
cotulifioned medium {derivedfrom J  limes more cells than the sample 
from tine 1-9). Molecular mass standards are indicated on the right. 
17V’'| j |  hands are risible at 16 and JO kd; cell tine MM ¡traduces VPF 
rarunits of 12! and 165 amino acids, which a n 1 faintly rfslhle as 
bands between J i  and lh  kd.
VPF1i31-producing lines I-3, I-4, and 1-11, and from the 
VPF.,a9-producing line III-8 (Figure 1, B). In these tu­
mors, as well as in the tumors from vector-transfected 
lines E1 and E2, the vector-encoded RNA for hygro- 
mycin phosphotransferase was also still expressed 
(not shown). Line I-9 produced only one small tumor 
after the first series of four injections, and was not 
included in further experiments.
In all xenografts, the levels of endogenous VPF 
mRNA were increased, as expected:13 However, in
tumors from the lines expressing the highest levels of 
recombinant VPF RNA (1-3 and 111-8), the levels of en­
dogenous VPF mRNA were about half of the level in 
line Mel57 tumors. This suggests that VPF might, pos­
sibly through inducing angiogenesis and preventing 
hypoxia, inhibit the expression of its own gene in vivo. 
The relative levels of recombinant VPF RNA and en­
dogenous VPF mRNA in the various transfected cell 
lines in vivo are summarized in Table 1.
Extrapolation of the higher efficiency of VPF pro­
duction from the recombinant VPF RNA than from the 
endogenous messenger (see above) to ihe in vivo 
situation suggests that the levels of recombinant VPF 
protein expressed by the VPF-transfected tumors 
greatly exceed the VPF levels expressed by the pa-
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rental line tumors. The level of recombinant VPF RNA 
in lino 1-3 in vivo is only 1.8-fold its endogenous 
messenger level, The amount of recombinant VPF 
protein produced would be, however, 13- to 83-fold 
the amount of VPF produced by Mel57 tumors. Tu­
mors from the lower expressing lines M  and 1-11, are 
still predicted to express 4- to 10-fold the VPF levels 
of Mel57 tumors (Table 1).
Growth of Transfected Melanoma Cells and 
Melanoma Xenografts
The In vitro growth curves of melanoma line Mei57, of 
the vector-transfected line E2, and the transfectant 
lines I-3 and IH-8 were determined in a colorimetric 
assay. All melanoma lines had growth ratos compa­
rable to the parental line with slightly higher growth
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rates for 1-3 and E2 at a serum concentration of 10% 
(Figure 4a), but a slightly lower rate for I-3 at 2% 
serum (Figure 4b). VPF expression did not influence 
growth in vitro in an autocrine way, since addition of 
exogenous recombinant VPF protein did not alter the 
growth rate of the Mel57 line (data not shown). More­
over, hybridization of Northern blots using probes for 
murine fit and ffic-1 showed that transcripts coding for 
these VPF receptors were not detectable in the cul­
tured melanoma cell lines (data not shown), suggest­
ing that functional VPF receptors were not present, 
There was no overall relation between the growth 
rates in vitro and tumor growth in vivo. Tumors from 
line HI-8 had a significantly higher growth ratein  vivo 
than E2 or Mel57 line tumors, both of which lines had 
identical growth curves (Figure 4c). Line I-3 tumors 
had an intermediate growth rate.
The percentages of tumor necrosis were deter­
mined from formalin-fixed and H&E-stained sec­
tions. No significant differences between the lines 
were observed (data not shown). The patterns of 
necrosis were rather variable; afl lines produced 
some tumors with extensive necrosis (up to 60 to 
80% of cross sections), while most lines (1-11, I-4, 
IN-8, E1, and E2) also developed tumors with low 
necrosis percentages (10 to 40%). Although the 
higher levels of VPF expression in the VPF-trans- 
fected lines caused faster tumor growth, this did 
not result in a higher ratio of viable cells, which 
might have been expected if the increased level of 
VPF had increased the density of tumor blood 
vessels.
immunohistological Analysis o f 
VPF-Transfected Melanomas
Staining of xenograft sections from VPF-transfected 
lines with MEC 7.46 and with Ab against laminin or 
HSPG showed that all transfected tumors developed 
the aberrant vascular pattern and extracellular ma­
trix component distribution described previously. 
(Figure 7)™
To study the distribution of VPF in the melanoma 
xenografts, sections were stained with a polyclonal 
anti-VPF Ab. In general, low staining intensities 
were found, especially in control tumors (from lines 
Mel57, E1, or E2). Diffuse VPF staining throughout 
the tumors was found in cross sections of line I-3, 
I-4, and III-8 tumors, indicative of the fact that VPF 
is expressed constitutively by these tumors. More 
intense VPF staining was often seen in the stromal 
compartments of VPF-transfected tumors (Figure 
5, d and e) as well as of control tumors (Figure 5b).
VPF staining colocalized, in part, with endothelial 
cells, confirming the finding that VPF accumulates 
on tumor blood vessels, but it was also seen on 
stromal cells that did not stain with the endothelial 
marker (compare Figures 5b and 5c), Although 
especially VPFiag has a high affinity for heparin, 
VPF staining in tumors from the line expressing this 
variant, ill-8, or from other lines, did not colocalize 
with HSPG staining (not shown).
Hypoxia was suggested to be a cause for the 
observed upregulation of VPF expression in Mel57 
xenografts.33 This hypothesis predicts that higher 
levels of VPF should be expressed around necrotic 
areas in such tumors. In some sections of line Mel57, 
E1, and E2 tumors, staining for VPF was indeed most 
intense in cells lining necrotic areas (Figure 5a)v 
suggesting an influence of hypoxia on the induction 
of VPF expression in the control tumors. However, 
there was not always an intense VPF staining seen 
adjacent to necrosis, whereas in a very small line E1 
tumor without any necrosis VPF staining was already 
visible in the stroma (Figure 5b). Therefore, tumor 
necrosis appears to be neither necessary nor suffi­
cient for the induction of VPF expression, and mech­
anisms other than hypoxia must be involved in this 
induction as well.
To test the expression of VPF protein in human 
patient melanoma lesions, cryosections of primary 
melanoma and melanoma metastasis were stained 
with polyclonal anti-VPF Ab. In all cases the pres­
ence of VPF could be detected, although the levels 
varied considerably. Figure 6 shows VPF staining 
in two different metastatic lesions. Figure 6a shows 
a pigmented lesion with a nodular growth pattern 
that contained a subpopulation of tumor cells that 
stained intensely for VPF. A metastatic lesion with 
a diffuse architecture showed diffuse positivity in 
the tumor cells and a marked staining of the vas­
cular bed (Figure 6b).
Examination of Vascular Permeability in the 
Transfectant Xenografts
Since VPF is an inducer of vascular permeability/'19
the permeability of the blood vessels for proteins 
may be enhanced in tumors derived from the VPF- 
transfected lines. This was tested by i.v. injections of 
fluorescein-conjugated albumin (FITC-BSA), and 
subsequent examination of the tumors.
in tumors from line Mel57 or from vector-trans- 
fected lines, 2 minutes and 10 minutes after injection 
very little extravasation of tracer had occurred: fluo­
rescence was almost exclusively seen within the vas-
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Figure 6, /.ocafixation of VPF fmucin in bttnian patient melanoma 
metastasis fusions. Cryosections nvre stainwf with a polyclonal and- 
VJV'Ah. a.- Pigmented (brown) lesion shows Java t Intense intracellular 
staining (red)for VP/'pwleiiL 5: fusion with a diffuse gnnvih [mtiern 
shows dijfuse uvak staining for VPh\ wbewas vascalar ceils are wore 
pnmiiuentiy stained. Magnification, X too.
As a consequence of this higher vascular perme­
ability, the formation of an extravascuiar fibrin matrix 
may be favored, facilitating the growth of new blood 
vessels,3  ^ or directing the pattern in which angio- 
genesis takes place. Staining for fibrinogen/fibrin in 
cross sections of these tumors did not show signifi­
cant differences in the distribution of fibrin, however. 
Fibrin staining was most intense in the vascular 
walls, but some fibrin deposition was also visible as 
short protrusions from blood vessels in all types of 
tumors (Figure 7, e and j). The network of extravas­
cuiar fibrin was certainly not more extensive in VPF- 
overproducing tumors. Apparently, extravasated fi­
brin was deposited close to the blood vessels, and 
protein leakage from tumor vessels was not rate- 
limiting for the development of an extravascuiar fibrin 
matrix,
Metastatic Properties of the Transfectant 
Xenografts
Because tumor angiogenesis is believed to be es­
sential for tumor growth and metastasis,1""3 the al­
tered vascular phenotype caused by a different VPF 
expression pattern may also change the growth rate 
and the metastatic potential of the tumors. To test 
this, cells of the lines E2, 1-3, and 111-8 were injected 
s.c, in groups of 20 mice each. The parental mela­
noma line Mel57 is of an earlier passage than all the 
transfected lines at the time of injection, since the 
latter lines have all been cloned and selected in 
hygromycin-contalning medium for a prolonged pe­
riod (see Materials and Methods). Therefore, vector- 
transfected line E2 is probably a better control in this 
experiment than parental cell line Mel57. Weekly 
measurements of the tumor volumes showed that the 
growth rates of the VPF-transfected xenografts were 
significantly increased compared with that of the E2 
line (see above, and Figure 4c), After 7 weeks, the 
mice were sacrificed. Previous experiments had in­
dicated that the incidence of metastasis in tumors 
from the maternal line approached a value of 50% at 
that time, so that this time schedule would allow an 
estimate of both an increase and a decrease in the 
metastasis frequency. The tumors were excised and 
weighed and the numbers of lung metastases esti­
mated. Tabfe 3 shows that the VPF-transfected xe­
nografts have comparable densities but a signifi­
cantly higher weight than the control E2 tumors. 
Similar frequencies of metastasis were found, but the 
metastatic burden, ie, the number of metastases per 
affected lung, was significantly higher in the VPF 
transiectants. A correlation between the number of 
metastases in a lung section and the size of the 
corresponding primary tumor was not found (not 
shown).
Discussion
The aim of this study was to test whether a change 
from an inducible to a constitutive VPF expression 
pattern in melanoma cells affects the development of 
the tumor vascular bed, and if so, whether the level 
of VPF expression influences the vascular pattern. 
This question was inspired by the observation that
i
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Table 3. Biological Hehavior o f  Xenografts o f  177’- or Vector~Tr<i)isfected M elanoma lines
Tumor weight* (n) Tumor volume1 (n) Tumor density|; (n) Metastatic incidence^ Metastatic burden1 (n)
•  »»<
E2 0.88 ± 0.36(17) 0.89 ± 0.44 (17) 1.1 ± 0.2 (17) 11/20(55%) 3.1 ± 2.8 (11)
I-3 1.50 ± 1.08 (14) 1.56 ± 1.36 (14) 1.1 + 0.2(16) 9/17(53%) 8.0+10.8(9)
-8 2.16 ± 0.77(15) 2.31 ± 0,73(15) 0.9 ±0.1 (17) 8/18(44%) 9.1 ± 5.8 (8)
* Weight (g) ±  SD of lumors excised 7 weeks after inoculation, Statistical level of significance of the difference between the tumor 
weight of E2 and 1-3, p < 0,02, and oi E2 and 111-8, p < 0.001.
1‘ Volume (ctrv3) ±  SD of tumors measured 7 weeks after inoculation.
:|; Density (g/cmn) ±  SD of all measured tumors.
§ Number of cases with one or more lung metastases/total number of mice in the group,
It Mean ± SD of the number of metastases counted in cross-sections of the lungs containing tumor cells, In the III-8 group one case with 
an excessive amount of metastases { -100) was omilted. Statistical level of significance of the difference between the metastatic burden of 
line E2 and f-3, p  < 0,08, and E2 and MI-8, p < 0.01.
human melanoma lines differed in their pattern of 
VPF expression. Some lines, such as BLM, had a 
constitutively high level of VPF expression, whereas 
other melanoma lines with a somewhat different vas­
culature, such as Mel57, had a much lower expres­
sion level of VPF in culture, which In vivo was upregu- 
lated to the same level as that found in line BLM.33 
By transfection of line Mel57, several lines with a high 
basal level of VPF expression were obtained. These 
lines provided a model to test the influence of the 
VPF expression pattern in vivo,
An intriguing observation using the transfectant 
lines in vitro was the higher efficiency of translation of 
the recombinant VPF RNA compared with that of the 
endogenous VPF mRNA. In the 5' noncoding se­
quence of the endogenous VPF messenger, a GC- 
rich region Is present as well as several AUG and 
GUG alternative Initiation codons.4'1 Such features 
have also been found in the 5' noncoding region of 
the PDGF-B chain transcript, where they have a pro­
found inhibitory effect on the translation efficient 
cy.'KV,/ The 5' region of the recombinant VPF RNA 
contained a vector-encoded SV40-derived leader 
and only a 21 base stretch of the 5' noncoding 
sequence of the VPF gene. The higher translation 
efficiency of this recombinant transcript indicates 
that also in the 5' noncoding region of the VPF mRNA 
sequences are present that inhibit translation.
When studying and interpreting the differences in 
biological behavior induced by the transfection of 
VPF expression constructs, one should be aware of 
unexpected genetic changes that can occur during 
the transfection and selection procedure. Mutations 
may yield a selective advantage in vivo and cause 
heterogeneity of the tumor cell population. However, 
both the vascular patterns, the vascular permeabil­
ity, and the matrix distribution were phenotypically 
stable within the parental line Mel57, the vector- 
transfected lines, and the various VPF-transfected 
lines. Also, morphological heterogeneity within tu­
mors was rarely seen. Therefore, there is no reason
to assume that the observed differences in tumor 
morphology and physiology are caused by unex­
pected genetic changes; they are much more likely 
to be caused by the experimentally intended 
changes in the VPF expression pattern.
The lines transfected with VPF expression con­
structs indeed produced tumors with a strikingly dif­
ferent vascular pattern from the parental line or vec­
tor-transfected lines. The vascular pattern seen in 
tumors from the VPF-transfected lines was, unex­
pectedly, also very different from that in other mela­
noma lines constitutively expressing VPF, such as 
BLM.33 This comparison is not quite appropriate, 
however, as VPF is probably not the only determinant 
of the vascular phenotype. Furthermore, the VPF 
expression levels of the transfectant lines in vivo are 
presumably an order of magnitude higher than the 
expression level of line BLM.
The aberrant vascular phenotype induced by the 
VPF-transfected lines in the present studies was not 
dependent on the level of recombinant VPF expres­
sion. It should be noted, however, that even in the 
line with the lowest expression level (1-11), VPF was 
probably still overexpressed by a factor of 4 to 9 
compared with normal Mel57 xenografts. Transfec­
tant lines with even lower expression levels than line 
M l  would have been useful, but were difficult to 
identify by Northern blotting because of their ex­
tremely low levels of recombinant VPF RNA.
The vascular pattern in tumors from line 111-8, 
which expresses the heparin-binding VPFUU) vari­
ant, was not significantly different from the pattern 
in the tumors producing the diffusible variant 
VPF,.,,. This indicates that this molecular variant is 
biologically active and that it must, at least in part, 
be released from the producing cells. Proteases 
such as plasmin may be present in the tumor 
parenchyma, which can release a biologically ac­
tive part of VPF1M1).'1M
It is difficult to give an explanation for the devel­
opment of the aberrant vascular phenotype in the
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tumors from VPF-transfected lines. A suitable expla­
nation for the absence of tumor-penetrating vessels 
in the VPF-overproducing tumors could be the ab­
sence of a VPF concentration gradient that would 
develop in control tumors as a result of hypoxia- 
induced VPF expression. However, the correlation 
between tumor necrosis and VPF staining was not as 
strong as might have been expected if hypoxia were 
the only inductive factor. Also, the fact that different 
vascular patterns had already evolved in very small 
tumors from lines El and 1-3, without any signs of 
necrosis, makes this hypothesis unlikely.
Varying degrees of extravascuiar fibrin deposition 
could influence the patterns of neovascularization in
the tumors as well.^"Although the permeability of the 
tumor vessels for proteins was, as expected, chron­
ically increased in the tumors producing recombi­
nant VPF, it did not lead to a more extensive fibrin 
network in these tumors. Extravasated fibrinogen 
may be quickly converted into fibrin and be depos­
ited close to the blood vessels from which it origi­
nated. Furthermore, along with larger amounts of 
extravasating fibrinogen, also larger amounts of 
plasminogen may leak from the vessels. This may be 
activated by plasminogen activators, which are 
probably expressed in increased amounts by endo­
thelial cells because of the action of VPF/-1"’ and 
which may also be expressed by the tumor cells. 
Plasmin could then remove most of the deposited 
fibrin. An enhanced activity of proteinases in the 
tumors from VPF-transfected lines could also explain 
the low amounts of matrix proteins detected within 
their tumor cell nests. It is therefore of great interest 
to investigate in future studies the presence and 
distribution of specific proteases in these tumors.
Although changing VPF expression in a melanoma 
line from inducible to constitutive does change the 
pattern of tumor vascularization qualitatively, the 
mechanism by which VPF influences this pattern is 
still unclear. The determination of the vascular pat­
tern is clearly dependent upon a number of param­
eters that are not quite understood, of which VPF 
expression is one. Initially, we expected that overex­
pression of VPF would increase the number of tumor 
blood vessels, a finding that was very recently re­
ported in a tumor xenograft model of human breast 
carcinoma.4M However, because of the dramatic 
change in architecture, it was impossible to estimate 
the density of functional blood vessels in the VPF- 
transfectant tumors. I lence, our model appears not 
to bo a suitable system to test whether the number of 
tumor blood vessels is rate-limiting to the process of 
metastasis, in contrast to the described breast car­
cinoma model.,|M However, it was not tested in this
latter model whether in vivo upregulation of VPF ex­
pression occurred. Because of this, the differences 
in VPF expression in vivo between transfected and 
non-transfected tumors were unknown. Therefore, 
further studies on the role of VPF in angiogenesis 
and tumor vessel function are required.
Immunostaining of human melanoma lesions 
showed that VPF protein is expressed in patient ma­
terial. Both nodular and diffuse growth patterns were 
observed, which seemed to be accompanied by a 
different staining pattern for VPF. However, the con­
sistence of this finding will have to be addressed in a 
more extensive study.
The notion that the tumor vasculature is important 
for metastasis urged us to study the consequences 
of a change in vascular type for the metastatic po­
tential of the tumors. The vector-transfected E2 line 
was used as a control, since the parental line Mel57 
was of a lower passage at the time of injection into 
mice and had not undergone the transfection and 
selection procedures, and therefore may not be a fair 
control line in these experiments. On the other hand, 
unexpected events may have genetically altered line 
E2 (as discussed above). This possibility is hard to 
verify, but it does limit the reliability of line E2 as a 
control in the metastasis experiment. Although the 
VPF-transfected xenografts had increased growth 
rates compared with the control, we could not dem­
onstrate significant differences in the metastatic in­
cidence between these lines, ie, the percentage of 
mice that had one or more metastases in the exam­
ined lung sections. A remarkable finding was, how­
ever, that the number of metastases per affected 
lung was considerably higher in mice carrying VPF- 
transfected tumors than in the controls. It is unclear 
at what stage of the multi-step process of metastasis
this effect is caused, A correlation with growth rate or 
size of the tumors was not found, but there might bo 
a relation with the increased vascular permeability in 
the VPF-transfected xenografts.
The presence of laminin and proteoglycans in the 
stromal septa of VPF-overproducing melanomas 
suggested that these matrix proteins act as a basal 
membrane, forming a barrier between tumor cells 
and the highly vascular stroma. Of course, the pres­
ence of such a membrane may counteract meta­
static spread and would hamper a straightforward 
interpretation of the findings obtained in this study.
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